

Genzyme Corporation (GENZ)

Analyst Schedule

(Unaudited, amounts in thousands, except percentage amounts)

	Q2-08	Q3-08	Q4-08	Q1-09	Q2-09	Q2-09 vs. Q2-08 % B/(W)	FY 2007	FY 2008	YTD 06/30/09
Total revenues:									
Genetic Diseases									
Cerezyme	\$ 319,360	\$ 309,280	\$ 306,034	\$ 295,970	\$ 298,087	(7%)	\$ 1,133,153	\$ 1,238,977	\$ 594,057
Fabrazyme	126,608	125,619	125,558	122,201	134,302	6%	424,284	494,260	256,503
Myozyme	77,222	76,663	74,967	67,392	79,273	3%	200,728	296,176	146,665
Aldurzyme	38,834	38,236	37,579	36,837	39,190	1%	-	151,664	76,027
Other Genetic Diseases	10,437	11,367	14,039	14,650	17,301	66%	8,314	45,615	31,951
Total Genetic Diseases product and service revenue	572,461	561,165	558,177	537,050	568,153	(1%)	1,766,479	2,226,692	1,105,203
R&D Revenue	-	-	-	-	-		1,059	-	-
Total Genetic Diseases	572,461	561,165	558,177	537,050	568,153	(1%)	1,767,538	2,226,692	1,105,203
Cardiomatabolic and Renal									
Renagel and Renvela (including Sevelamer)	168,567	170,992	169,476	170,599	175,398	4%	602,670	677,729	345,997
Hectorol	30,852	33,825	34,400	33,030	28,981	(6%)	115,708	128,153	62,011
Subtotal	199,419	204,817	203,876	203,629	204,379	2%	718,378	805,882	408,008
Thyrogen	39,448	38,153	37,062	38,826	42,860	9%	113,587	148,448	81,686
Other Cardiomatabolic and Renal	333	573	496	494	753	126%	103	1,653	1,247
Total Cardiomatabolic and Renal product and service revenue	239,200	243,543	241,434	242,949	247,992	4%	832,068	955,983	490,941
R&D revenue	85	56	27	13	8	(91%)	1,200	200	21
Total Cardiomatabolic and Renal	239,285	243,599	241,461	242,962	248,000	4%	833,268	956,183	490,962
Biosurgery									
Synvisc	70,927	67,513	68,512	63,171	82,417	16%	242,319	263,094	145,588
Sepra products	34,780	33,001	35,278	34,304	36,038	4%	104,318	133,663	70,342
Other Biosurgery	24,690	21,787	20,908	21,485	20,002	(19%)	74,673	91,698	41,487
Total Biosurgery product and service revenue	130,397	122,301	124,698	118,960	138,457	6%	421,310	488,455	257,417
R&D revenue	818	661	563	562	870	6%	5,337	2,645	1,432
Total Biosurgery	131,215	122,962	125,261	119,522	139,327	6%	426,647	491,100	258,849
Hematologic Oncology									
Total Hematologic Oncology product and service revenue	26,443	26,328	27,437	34,423	55,078	108%	69,927	102,899	89,501
R&D revenue	1,903	2,292	9,055	1,484	852	(55%)	7,006	14,439	2,336
Total Hematologic Oncology	28,346	28,620	36,492	35,907	55,930	97%	76,933	117,338	91,837
Other									
Genetic/Diagnostics product and service revenue	116,863	121,163	124,840	129,194	132,955	14%	410,917	477,614	262,149
Transplant product and service revenue	47,763	47,784	50,723	52,666	56,060	17%	174,826	192,200	108,726
Other product and service revenue	29,296	28,598	30,252	23,501	22,423	(23%)	108,577	119,155	45,924
Total Other product and service revenue	193,922	197,545	205,815	205,361	211,438	9%	694,320	788,969	416,799
R&D revenue	5,905	6,393	6,354	8,069	5,662	(4%)	14,813	24,757	13,731
Total Other	199,827	203,938	212,169	213,430	217,100	9%	709,133	813,726	430,530
Total revenues	\$ 1,171,134	\$ 1,160,284	\$ 1,173,560	\$ 1,148,871	\$ 1,228,510	5%	\$ 3,813,519	\$ 4,605,039	\$ 2,377,381

All amounts herein are presented in accordance with GAAP and are provided for quantitative analysis only and should be read in conjunction with the text of the Earnings Release and our audited financial statements filed with the Securities and Exchange Commission. Please refer to our Form 10-Q's and Form 10-K's for an in-depth discussion and analysis of our results of operations and financial position and for detailed information regarding specific material transactions in a particular period.